Skip to main content
Premium Trial:

Request an Annual Quote

HBIO Reports Net Loss, Higher Revenues for Q1; Works on Action Plan for Ailing Genomics, Proteomics Products

NEW YORK, May 7 (GenomeWeb News) - Harvard Bioscience yesterday reported increased revenues but a net loss for the first quarter of the year.

 

Revenues totaled $22.2 million, up from $19.5 million during the first quarter last year. Most product lines did well, according to the company. "However, our genomics, proteomics and high-throughput screening products delivered far less operating margin than we expected," said HBIO CEO Chane Graziano in a statement. "We are in the process of defining the actions necessary to enable these product lines to meet our growth and profitability objectives going forward. We expect to implement this action plan in the second quarter."

 

R&D expenses increased slightly, to $1.7 million, from $1.4 million during the same quarter in 2003.

 

HBIO's net loss for the quarter was $51,000, or $0 per share, down from a net income of $776,000, or $.03 per share, during the same period last year.

 

As of March 31, HBIO had $9.8 million in cash and cash equivalents. This is more than at the end of 2003, due to a positive operating cash flow.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.